YOSHIMURA KENICHI

Affiliation and department：
Job title： Professor
Other affiliations (1)：

Kobe University Visiting Professor

Research theme for competitive and other funds (11)：

2021 - 2024 国際共同臨床研究データの近代的構築と発展 ~最新の情報工学技術の融合による挑戦
2019 - 2023 がん臨床試験における患者の意思決定支援のための学習プログラム開発と実践知の可視化
2016 - 2020 Development of new inferential method using weighted permutation method for evaluation of sequential treatment strategy
2016 - 2020 Study of clinical states and infrastructure development of International co-operative clinical trial for childhood liver tumors by children's cancer study group
2016 - 2019 Establishment of therapeutic strategy for advanced gastrointestinal cancer with targeted alpha therapy

Show all

Papers (146)：

Kazushige Wakuda, Hiroyuki Yamaguchi, Hirotsugu Kenmotsu, Minoru Fukuda, Kentaro Ito, Yuko Tsuchiya-Kawano, Kentaro Tanaka, Taishi Harada, Yuki Nakatani, Satoru Miura, et al. A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L). JTO clinical and research reports. 2023. 4. 12. 100587-100587
Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, et al. Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data in brief. 2022. 45. 108558-108558
Hiroshi Wakabayashi, Anri Inaki, Kenichi Yoshimura, Toshinori Murayama, Yasuhito Imai, Tetsuya Higuchi, Megumi Jinguji, Tohru Shiga, Seigo Kinuya. Author Correction: A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma. Scientific Reports. 2022. 12. 1
Yoshinobu Yamamoto, Naohiro Yoshida, Tomonori Yano, Takahiro Horimatsu, Noriya Uedo, Noboru Kawata, Hiromitsu Kanzaki, Shinichiro Hori, Kenshi Yao, Seiichiro Abe, et al. Assessment of Outcomes From 1-Year Surveillance After Detection of Early Gastric Cancer Among Patients at High Risk in Japan. JAMA Network Open. 2022. 5. 8. e2227667-e2227667
Yukinori Ozaki, Junji Tsurutani, Toru Mukohara, Tsutomu Iwasa, Masato Takahashi, Yuko Tanabe, Hidetaka Kawabata, Norikazu Masuda, Manabu Futamura, Hironobu Minami, et al. Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). European journal of cancer (Oxford, England : 1990). 2022. 171. 193-202

ｍore...

MISC (50)：

Jun Masuda, Junji Tsurutani, Norikazu Masuda, Yuko Tanabe, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Hiroji Iwata, et al. Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2-metastatic breast cancer: WJOG11418B NEWFLAME trial. CANCER RESEARCH. 2021. 81. 4
Yukinori Ozaki, Shigehisa Kitano, Junji Tsurutani, Tsutomu Iwasa, Masato Takahashi, Toru Mukohara, Norikazu Masuda, Manabu Futamura, Hironobu Minami, Koji Matsumoto, et al. Immunological analysis of the combination therapy of nivolumab, paclitaxel and bevacizumab in patients with HER2negative MBC in NEWBEAT trial (WJOG9917BTR). CANCER RESEARCH. 2021. 81. 4
Hiroko Masuda, Tsutomu Iwasa, Toru Mukohara, Shinya Tokunaga, Koji Matsumoto, Naoki Niikura, Yasuaki Sagara, Yasuo Miyoshi, Akihiko Shimomura, Masato Takahashi, et al. Phase II study of trimebutine maleate and probiotics for abemaciclib-induced diarrhea in patients with ER-positive and HER2-negative advanced breast cancer (MERMAID) WJOG11318B. CANCER RESEARCH. 2020. 80. 4
Jun Masuda, Junji Tsurutani, Norikazu Masuda, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi, Masato Takahashi, Hiroji Iwata, Tsutomu Iwasa, Toru Mukohara, et al. Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial). CANCER RESEARCH. 2020. 80. 4
Yukinori Ozaki, Toru Mukohara, Junji Tsurutani, Masato Takahashi, Koji Matsumoto, Manabu Futamura, Norikazu Masuda, Shigehisa Kitano, Kenichi Yoshimura, Hironobu Minami, et al. A multicenter phase II study evaluating the efficacy of nivolumab plus paclitaxel plus bevacizumab triple-combination therapy as a first-line treatment in patients with HER2-negative metastatic breast cancer: WJOG9917B NEWBEAT trial. CANCER RESEARCH. 2020. 80. 4

ｍore...

Professional career (1)：

Ph.D. (The University of Tokyo)

Work history (5)：

2020/01/01 - Hiroshima University Hospital Professor
2019/08/01 - 2019/12/31 Hiroshima University Center for Integrated Medical Research Professor
2013/04/01 - 2014/07/31 Kobe University Hospital Associate professor
2008/05/01 - 2013/03/31 Kyoto University Translational Research Center Assistant professor
2005/04/01 - 2008/04/30 technical official, Ministry of Health, Lobour Researcher

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page